Finance

Lists
Outlook: 21.2% bullish·42.4% bearish
Go to analysis
XENE:NASDAQ
Xenon Pharmaceuticals Inc
$39.75
-30.69%
(-17.60) 1D
$39.80
+0.13% (+0.050)
After hours
Closed: Sep 18, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for XENE...
Open
$44.02
High
$44.85
Low
$39.08
Mkt. cap
3.85B
Avg. vol.
676.14K
Volume
17.95M
52-wk high
$72.66
52-wk low
$35.97
EPS
-$4.74
Beta
0.61
Shares outstanding
96.84M
No. of employees
364
Open
$44.02
High
$44.85
Low
$39.08
Mkt. cap
3.85B
Avg. vol.
676.14K
Volume
17.95M
52-wk high
$72.66
52-wk low
$35.97
EPS
-$4.74
Beta
0.61
Shares outstanding
96.84M
No. of employees
364
News stories
From web sources and news partners
About Xenon Pharmaceuticals Inc
CEO-
Employees364
Founded1996
HeadquartersVancouver, British Columbia, Canada
SectorBiotechnology
Websitexenon-pharma.com
Analyst ratings
Based on 16 analysts giving stock ratings to XENE in the past 3 months
Strong buy
Buy
15
Hold
1
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for XENE in the last 3 months.
Highest
Current $39.75
$90.00 (+126.42%)
Average
$70.75 (+77.99%)
Lowest
$46.00 (+15.72%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Gerberry
Bank of America Securities
Buy
Maintained
-
-
09/18/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
-
-
09/18/2026
Paul Choi
Goldman Sachs
Buy
Maintained
$75.00
+88.7%
09/17/2026
Laura Chico
Wedbush
Buy
Maintained
$55.00
+38.4%
09/18/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
09/18/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
$90.00
+126.4%
09/18/2026
Brian Abrahams
RBC Capital
Buy
Reiterated
$70.00
+76.1%
09/17/2026
Benjamin Burnett
Wells Fargo
Buy
Reiterated
$64.00
+61%
09/18/2026
Serge Belanger
Needham
Buy
Maintained
$60.00
+50.9%
09/18/2026
Douglas Tsao
H.C. Wainwright
Buy
Maintained
$74.00
+86.2%
09/18/2026
David Hoang
Deutsche Bank
Hold
Downgraded
$46.00
+15.7%
09/18/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/18/2026
Tessa Romero
J.P. Morgan
Buy
Maintained
$82.00
+106.3%
08/11/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$80.00
+101.3%
08/07/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$90.00
+126.4%
08/06/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
$63.00
+58.5%
06/22/2026
David Martin PhD
Bloom Burton
Buy
Maintained
$74.00
+86.2%
03/09/2026
Andrew Tsai
Jefferies
Buy
Reiterated
$100.00
+151.6%
03/09/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
$55.00
+38.4%
02/26/2026
Rudy Li
Wolfe Research
Buy
Initiated
$60.00
+50.9%
02/23/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
77.05M
87.70M
88.51M
99.22M
Cost of revenue
77.05M
87.70M
88.51M
99.22M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
19.28M
22.07M
23.82M
23.93M
Operating expense
19.28M
22.07M
23.82M
23.93M
Total operating expenses
96.34M
109.77M
112.33M
123.16M
Operating income
-96.34M
-109.77M
-112.33M
-123.16M
Other non operating income
-
-
-
-
EBT including unusual items
-90.22M
-104.72M
-104.87M
-111.32M
EBT excluding unusual items
-90.22M
-104.72M
-104.87M
-111.32M
Income tax expense
677.00K
538.00K
-2.57M
-585.00K
Effective tax rate
-0.75%
-0.51%
2.45%
0.53%
Other operating expenses
-
-
-
-
Net income
-90.90M
-105.26M
-102.30M
-110.74M
Net profit margin
-
-
-
-
Earnings per share
-1.15
-1.31
-1.17
-1.11
Interest and investment income
6.21M
5.34M
6.91M
12.14M
Interest expense
-
-
-
-
Net interest expenses
6.21M
5.34M
6.91M
12.14M
Depreciation and amortization charges
-
-
-
-
EBITDA
-95.70M
-109.16M
-111.74M
-122.60M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps